Tiziana Life Sciences (TLSA) Competitors

$0.64
+0.07 (+12.39%)
(As of 05/15/2024 ET)

TLSA vs. CNTX, GRFS, LVTX, MYNZ, NLSP, PHVS, ATNFW, SXTPW, ACONW, and AIMDW

Should you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Context Therapeutics (CNTX), Grifols (GRFS), LAVA Therapeutics (LVTX), Mainz Biomed (MYNZ), NLS Pharmaceutics (NLSP), Pharvaris (PHVS), 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Aclarion (ACONW), and Ainos (AIMDW). These companies are all part of the "medical" sector.

Tiziana Life Sciences vs.

Context Therapeutics (NASDAQ:CNTX) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, community ranking, institutional ownership and media sentiment.

Context Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 343.79%. Given Tiziana Life Sciences' higher probable upside, equities research analysts clearly believe Context Therapeutics is more favorable than Tiziana Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Context Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Tiziana Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

In the previous week, Context Therapeutics had 6 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 10 mentions for Context Therapeutics and 4 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.96 beat Context Therapeutics' score of 0.47 indicating that Context Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Context Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Tiziana Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Context TherapeuticsN/AN/A-$23.96M-$1.33-1.27
Tiziana Life SciencesN/AN/A-$15.40MN/AN/A

Context Therapeutics' return on equity of 0.00% beat Tiziana Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Context TherapeuticsN/A -136.03% -109.54%
Tiziana Life Sciences N/A N/A N/A

Context Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.

14.0% of Context Therapeutics shares are held by institutional investors. 9.4% of Context Therapeutics shares are held by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tiziana Life Sciences received 84 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 63.58% of users gave Tiziana Life Sciences an outperform vote while only 63.16% of users gave Context Therapeutics an outperform vote.

CompanyUnderperformOutperform
Context TherapeuticsOutperform Votes
12
63.16%
Underperform Votes
7
36.84%
Tiziana Life SciencesOutperform Votes
96
63.58%
Underperform Votes
55
36.42%

Summary

Context Therapeutics and Tiziana Life Sciences tied by winning 6 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLSA vs. The Competition

MetricTiziana Life SciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$65.46M$6.74B$5.08B$7.97B
Dividend YieldN/A2.73%37.04%3.93%
P/E RatioN/A14.08133.3116.26
Price / SalesN/A243.312,310.6978.94
Price / CashN/A35.2335.6431.30
Price / Book3.346.475.504.47
Net Income-$15.40M$137.90M$104.43M$216.49M
7 Day Performance-5.00%-0.24%1.06%1.89%
1 Month Performance27.03%1.26%2.54%4.24%
1 Year Performance-19.63%-1.01%6.53%10.74%

Tiziana Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNTX
Context Therapeutics
2.8075 of 5 stars
$1.72
-3.4%
$4.00
+132.6%
+207.2%$0.00N/A-1.155Gap Down
GRFS
Grifols
3.3423 of 5 stars
$6.80
-3.1%
$10.50
+54.4%
-14.5%$0.00$7.13B0.0023,737News Coverage
LVTX
LAVA Therapeutics
2.8853 of 5 stars
$3.00
+5.6%
$6.00
+100.0%
+58.8%$0.00$6.77M-1.8937Short Interest ↓
Gap Up
MYNZ
Mainz Biomed
1.6492 of 5 stars
$0.78
+5.4%
$6.00
+665.1%
-87.9%$0.00$900,000.00-0.4865Upcoming Earnings
Short Interest ↑
Gap Up
High Trading Volume
NLSP
NLS Pharmaceutics
0 of 5 stars
$0.14
flat
N/A-85.5%$0.00N/A0.006Gap Down
PHVS
Pharvaris
1.2096 of 5 stars
$22.62
-0.3%
$32.50
+43.7%
+160.0%$0.00N/A-7.9682Short Interest ↑
Analyst Revision
ATNFW
180 Life Sciences
0 of 5 stars
$0.01
flat
N/A-43.1%$0.00N/A0.004Gap Down
SXTPW
60 Degrees Pharmaceuticals
0 of 5 stars
$0.11
-8.7%
N/AN/A$0.00$253,573.000.002Gap Down
ACONW
Aclarion
0 of 5 stars
$0.05
flat
N/AN/A$0.00$75,404.000.004Gap Down
AIMDW
Ainos
0 of 5 stars
$0.06
-26.2%
N/A-87.4%$0.00$122,112.000.0046Gap Down

Related Companies and Tools

This page (NASDAQ:TLSA) was last updated on 5/15/2024 by MarketBeat.com Staff

From Our Partners